Glaxo, Theravance Launch Relvar Ellipta in Japan

The latest medicament from GlaxoSmithKline (NYSE: GSK  ) and Theravance (NASDAQ: THRX  ) is about to hit pharmacy shelves in Japan. The latter announced in an SEC filing that the two companies' Relvar Ellipta treatment has been launched in that country, less than two months after it won approval by the Japanese Ministry of Health, Labor and Welfare. Theravance is now obligated to make a milestone payment of $10 million to GlaxoSmithKline contingent upon the launch.

Relvar Ellipta is used to treat asthma in patients 12 and older. It also combats chronic obstructive pulmonary disease (known better as COPD) in adults. It is taken once per day in the form of a dry powder inhaler.

The news comes several weeks after the two firms announced that Relvar Ellipta had been granted marketing authorization in 31 European countries.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2758510, ~/Articles/ArticleHandler.aspx, 10/20/2014 4:32:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement